Retatrutide phase 3 data shows sustained metabolic improvements at 68 weeks
Interim results from the TRIUMPH program suggest the triple agonist maintains its lead over dual-incretin therapy on weight and liver-fat endpoints.
ResearchTirzepatide
Also known as: Mounjaro, Zepbound
ClassDual GIP/GLP-1 receptor agonist
Research statusFDA-approved (branded forms)
CategoryGLP-1 / incretin
Independent tests2
Studies indexed2
Overview
Tirzepatide activates both GIP and GLP-1 receptors, a dual mechanism that produced the strongest weight-loss results seen in a phase 3 obesity program at the time of its approval (SURMOUNT-1 reported mean reductions above 20% at the highest dose).
Like semaglutide, tirzepatide has developed a substantial compounded and gray-market presence that the Institute actively tests.
Research & Studies
Studies library-
Tirzepatide versus semaglutide in adults with obesity (SURMOUNT-5)
Direct comparison favoring tirzepatide on weight endpoints at matched treatment intent.
-
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
Up to 20.9% mean weight reduction at 72 weeks; established dual-incretin agonism at phase 3 scale.
Independent Testing
Testing databaseLaboratory verification of Tirzepatide products across the companies we index.
Tirzepatide NextGen Peptides
Purity 98.2% Discrepancy
Tirzepatide Apex Peptides
Purity 98.8% Verified
Latest Coverage
FDA updates guidance on peptide compounding: what changes and when
The August guidance clarifies bulk-substance eligibility and signals enforcement priorities for the next year.
Regulation
We Independently Tested 20 Peptide Samples. Here’s What We Found.
Six months, three laboratories, and 20 anonymously purchased samples from 12 companies. Purity ranged from 61% to 99.2% — and two products failed verification entirely.
Special ReportCommunity Discussions
Forum 68 replies
46 replies
31 replies
16 replies
The Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements